The first non-invasive Biomarker to track the efficacy and effectiveness of Senolytic Drugs
Researchers at the Buck Institute have developed a non-invasive, novel biomarker test to track and measure senolytics’ performance. Senolytics are a group of drugs which selectively eliminates senescent cell. This discovery will be crucial in the development of treatments for a variety of age-related chronic conditions, from Alzheimer’s to arthritis and lung disease. This biomarker, a unique lipid signaling metabolite that is normally only intracellular but is released by senescent cell death, is a unique metabolite. This metabolite can be detected in urine and blood, allowing for non-invasive testing. This metabolite can be detected via a companion assay to verify the performance of senolytic drug candidates.
The number of biotech firms racing to create drugs that eliminate senescent cell continues to grow, and so does the list of age-related illnesses definitively linked with cellular senescence, said Buck professor Judith Campisi Ph.D. Senior scientist on the research. The field is more promising than ever, but the lack of simple biomarkers to track and measure efficacy has been a barrier to progress. We are thrilled to introduce this new biomarker into the field, and we look forward to its use in the clinic.\”
Source:
https://medicalxpress.com/news/2021-04-non-invasive-biomarker-track-efficacy-senolytic.html
